Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer
November 21 2017 - 7:30AM
Business Wire
Biogen (Nasdaq: BIIB) announced today the appointment of Jeffrey
D. Capello as Executive Vice President and Chief Financial Officer
effective as of December 11, 2017.
Mr. Capello will lead Biogen’s Business Planning, Tax, Treasury,
Internal Audit, Accounting, and Investor Relations functions. He
will report to Michel Vounatsos, CEO of Biogen, will be a member of
the Executive Committee, and will be based in Cambridge, Mass.
Mr. Capello brings 26 years of experience in finance. Most
recently he was Executive Vice President and Chief Financial
Officer of Beacon Health Options Inc. His previous experience
includes founding and running his own company, Monomy Advisors, and
serving as Chief Financial Officer of Ortho Clinical Diagnostics,
Boston Scientific Corporation, and Perkin Elmer. Earlier in his
career he was also a partner in the Boston and Amsterdam offices of
PwC.
Mr. Capello is a certified public accountant. He holds a B.S. in
Business Administration from the University of Vermont and an
M.B.A. in Accounting from Harvard Business School. Drafted by the
Buffalo Sabres in the National Hockey League, Mr. Capello played
two seasons for their American Hockey League club.
“I am very excited to join Biogen, a company which is recognized
as a pioneer and a leader in treating neurological diseases,” said
Mr. Capello. “I look forward to working with colleagues around the
world in our mission to make a difference in the lives of
patients.”
“We are fortunate to have Jeff join Biogen given the depth and
breadth of his experience,” said Mr. Vounatsos. “He comes to Biogen
at an exciting time as we execute our business strategy, pursue
business development opportunities and build our pipeline.”
About BiogenAt Biogen, our mission is clear: we are
pioneers in neuroscience. Biogen discovers, develops, and delivers
worldwide innovative therapies for people living with serious
neurological and neurodegenerative diseases. Founded in 1978 as one
of the world’s first global biotechnology companies by Charles
Weissman, Heinz Schaller, Kenneth Murray and Nobel Prize winners
Walter Gilbert and Phillip Sharp, Biogen has the leading portfolio
of medicines to treat multiple sclerosis; has introduced the first
and only approved treatment for spinal muscular atrophy; and is
focused on advancing neuroscience research programs in Alzheimer’s
disease and dementia, neuroimmunology, movement disorders,
neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and
acute neurology. Biogen also manufactures and commercializes
biosimilars of advanced biologics. We routinely post information
that may be important to investors on our website at
www.biogen.com. To learn more, please visit www.biogen.com and
follow us on social media – Twitter, LinkedIn, Facebook,
YouTube.
Biogen Safe HarborThis press release contains
forward-looking statements, made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements relating to our business activities, our
strategy and plans, the potential of our commercial business and
pipeline programs, and the expected benefits from Mr. Capello’s
appointment as Executive Vice President and Chief Financial
Officer. These forward-looking statements may be accompanied by
words such as “aim,” “anticipate,” “believe,” “could,” “estimate,”
“except,” “forecast,” “intend,” “may,” “plan,” “potential,”
“possible,” “will,” and other words and terms of similar meaning.
You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including, without limitation: risks relating to
management and key personnel changes; failure to compete
effectively; difficulties in obtaining and maintaining adequate
coverage, pricing, and reimbursement for our products; potential
future healthcare reforms; the occurrence of adverse safety events;
failure to protect and enforce our data, intellectual property, and
other proprietary rights and uncertainties relating to intellectual
property claims and challenges; uncertainty of success in
developing, licensing, or acquiring other product candidates or
additional indications for existing products; delay in approval of
our drug candidates; product liability claims; and third party
collaboration risks. The foregoing sets forth many, but not all, of
the factors that could cause actual results to differ from our
expectations in any forward-looking statement. Investors should
consider this cautionary statement, as well as the risk factors
identified in our most recent annual or quarterly report and in
other reports we have filed with the U.S. Securities and Exchange
Commission. These statements are based on our current beliefs and
expectations and speak only as of the date of this press release.
We do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of new information,
future developments or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171121005045/en/
BiogenMEDIA CONTACT:Matt Fearer, +1
781-464-3260public.affairs@biogen.comorINVESTOR CONTACT:Matt
Calistri, +1 781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024